Tags

Type your tag names separated by a space and hit enter

Acute management of migraine: triptans and beyond.
Curr Opin Neurol 1999; 12(3):261-7CO

Abstract

Migraine is a paroxysmal disorder characterized by attacks of headache, nausea, vomiting, photophobia and phonophobia, and malaise. This review summarizes new treatment options for the therapy of acute attacks. Sumatriptan was the first specific serotonin-1B/D agonist for the treatment of acute migraine attacks. Apart from the oral and subcutaneous formulation, it is also available as nasal spray and suppository. The other new migraine drugs zolmitriptan, naratriptan, rizatriptan and eletriptan differ in their pharmacological profiles, which translates into minor differences in efficacy, headache recurrence and side-effects. Importantly, in clinical practice individual patients may show a preference for one treatment over another. New drugs in migraine treatment include substance-P antagonists, nitric oxide synthetase inhibitors and calcitonin gene-related peptide antagonists.

Authors+Show Affiliations

Department of Neurology, University of Essen, Germany. h.diener@uni-essen.deNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

10499171

Citation

Diener, H C., and V Limmroth. "Acute Management of Migraine: Triptans and Beyond." Current Opinion in Neurology, vol. 12, no. 3, 1999, pp. 261-7.
Diener HC, Limmroth V. Acute management of migraine: triptans and beyond. Curr Opin Neurol. 1999;12(3):261-7.
Diener, H. C., & Limmroth, V. (1999). Acute management of migraine: triptans and beyond. Current Opinion in Neurology, 12(3), pp. 261-7.
Diener HC, Limmroth V. Acute Management of Migraine: Triptans and Beyond. Curr Opin Neurol. 1999;12(3):261-7. PubMed PMID: 10499171.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Acute management of migraine: triptans and beyond. AU - Diener,H C, AU - Limmroth,V, PY - 1999/9/28/pubmed PY - 1999/9/28/medline PY - 1999/9/28/entrez SP - 261 EP - 7 JF - Current opinion in neurology JO - Curr. Opin. Neurol. VL - 12 IS - 3 N2 - Migraine is a paroxysmal disorder characterized by attacks of headache, nausea, vomiting, photophobia and phonophobia, and malaise. This review summarizes new treatment options for the therapy of acute attacks. Sumatriptan was the first specific serotonin-1B/D agonist for the treatment of acute migraine attacks. Apart from the oral and subcutaneous formulation, it is also available as nasal spray and suppository. The other new migraine drugs zolmitriptan, naratriptan, rizatriptan and eletriptan differ in their pharmacological profiles, which translates into minor differences in efficacy, headache recurrence and side-effects. Importantly, in clinical practice individual patients may show a preference for one treatment over another. New drugs in migraine treatment include substance-P antagonists, nitric oxide synthetase inhibitors and calcitonin gene-related peptide antagonists. SN - 1350-7540 UR - https://www.unboundmedicine.com/medline/citation/10499171/Acute_management_of_migraine:_triptans_and_beyond_ L2 - http://dx.doi.org/10.1097/00019052-199906000-00004 DB - PRIME DP - Unbound Medicine ER -